Novo Nordisk A/S (NVO) is next scheduled to report earnings on Nov 4, 2026. The consensus analyst EPS estimate for the upcoming quarter is $0.80.
Equity Rank's fundamental strength composite scores NVO at 73.6/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at -23.3% per year and gross margin has moved -2.9 pp. Its SAVE composite score has moved -1.4 over the past 30 days.
Equity Rank calculates fair value for NVO by blending 19 valuation methods (8–15 run per security depending on data availability), including DCF, Graham Number, Price-to-Free-Cash-Flow, EPV, Three-Stage DCF, DDM, Residual Income, and Justified Price-to-Book. Each model is weighted by historical sector accuracy and updated regularly. Informational only — not investment advice.
Novo Nordisk A/S (NVO) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Novo Nordisk A/S (NVO) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks